UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 12, 2024
INSMED INCORPORATED
(Exact name of registrant as specified in its charter)
|
Virginia
|
000-30739
|
54-1972729
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
700 US Highway 202/206
Bridgewater, New Jersey
|
|
08807
(Zip Code)
|
|
(Address of principal executive offices)
|
|
|
Registrant’s telephone number, including area code: (908) 977-9900
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
|
Common Stock, par value $0.01 per share
|
INSM
|
Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the
Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 8.01 – Other Events.
As previously disclosed, on March 8, 2024, Insmed Incorporated (the “Company”) received notice of the exercise by AstraZeneca AB (“AstraZeneca”) of its second and
final option (the “Final Option”) under the License Agreement, dated October 4, 2016, by and between the Company and AstraZeneca (the “License Agreement”), to further develop and, if approved, commercialize brensocatib in the indications of chronic
obstructive pulmonary disease (“COPD”) or asthma. On June 12, 2024, the negotiation period following such exercise of the Final Option expired. No agreement was reached between the Company and AstraZeneca to permit AstraZeneca to further develop
and, if approved, commercialize brensocatib in the indications of COPD or asthma. The Company retains full worldwide development and commercialization rights for brensocatib in all indications other than COPD or asthma and AstraZeneca has no
further development or commercialization rights for brensocatib in COPD, asthma or any other indication.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Dated: June 13, 2024
|
INSMED INCORPORATED
|
| |
|
| |
By:
|
/s/ Michael A. Smith
|
| |
Name:
|
Michael A. Smith
|
| |
Title:
|
Chief Legal Officer and Corporate Secretary
|